Pazopanib and sunitinib trigger autophagic and non-Autophagic death of bladder tumour cells

British Journal of Cancer

Volumn 109, Issue 4, 2013, Pages 1040-1050

  Santoni, M ^a   Amantini, C ^b   Morelli, M B ^b   Liberati, S ^b,c   Farfariello, V ^b,d   Nabissi, M ^b   Bonfili, L ^b   Eleuteri, A M ^b   Mozzicafreddo, M ^b   Burattini, L ^a   Berardi, R ^a   Cascinu, S ^a   Santoni, G ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; CATHEPSIN B; MESSENGER RNA; OXYGEN RADICAL; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

ARTICLE; AUTOPHAGY; BLADDER CANCER; CANCER CELL CULTURE; CELL ASSAY; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; AUTOPHAGY; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MEMBRANE POTENTIAL, MITOCHONDRIAL; NECROSIS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; REACTIVE OXYGEN SPECIES; SULFONAMIDES; URINARY BLADDER NEOPLASMS;

EID: 84883156825     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.420     Document Type: Article

References (60)

1. Bellmunt J, González-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A (2011) Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 22: 2646-2653.
2. Chan ES, Patel AR, Hansel DE, Larchian WA, Heston WD (2012) Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model. Urology 80(736): e1-e5.
3. D'Eletto M, Farrace MG, Falasca L, Reali V, Oliviero S, Melino G, Griffin M, Fimia GM, Piacentini M (2009) Transglutaminase 2 is involved in autophagosome maturation. Autophagy 5: 1145-1154.
4. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1381.
5. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6: 734-745.
6. Ferri KF, Kroemer G (2001) Organelle-specific initiation of cell death pathways. Nat Cell Biol 3: E255-E263.
7. Funk RS, Krise JP (2012) Cic amphiphilic drug cause a marked expansion of apparent lysosomial volume: implications for an intracellular distributionbased drug interaction. Mol Pharm 9: 1384-1395.
8. Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, Boyle MG, Trout A, Flaherty AM, Bajorin DF (2010) Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 28: 1373-1379.
9. Gerullis H, Otto T, Ecke TH (2012) Target agents in second-line bladder cancer therapy. Anticancer Drugs 23: 1003-1015.
10. Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C, Otto T (2013) Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. Anticancer Drugs 24: 422-425.
11. Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM (2011) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 17: 7337-7346.
12. Gozuacik D, Kimchi A (2004) Autophagy as cell death and tumor suppressor mechanism. Oncogene 23: 2891-2906.
13. Groth-Pedersen L, Jäättelä M (2010) Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett 332: 265-274.
14. Ha SD, Ham B, Mogridge J, Saftig P, Lin S, Kim O (2009) Cathepsin B-mediated autophagy flux facilitates the anthrax toxin receptor-2-mediated delivery of anthrax lethal factor in the cytoplasm. J Biol Chem 285: 2120-2129.
15. Jaakkola PM, Pursiheimo J-P (2009) p62 degradation by autophagy: another way for cancer to survive under hypoxia. Autophagy 5: 410-412.
16. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer Statistics, 2010. CA Cancer J Clin 60: 277-300.
17. Johansen T, Lamark T (2011) Selective autophagy mediated by autophagic adapter proteins. Autophagy 7: 279-296.
18. Kaufmann AM, Krise JP (2007) Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci 96: 729-746.
19. Kirkegaard T, Jäättelä M (2009) Lysosomal involvement in cell death and cancer. Biochim Biophys Acta 1793: 746-754.
20. Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, Mizushima N, Iwata J, Ezaki J, Murata S, Hamazaki J, Nishito Y, Iemura S, Natsume T, Yanagawa T, Uwayama J, Warabi E, Yoshida H, Ishii T, Kobayashi A, Yamamoto M, Yue Z, Uchiyama Y, Kominami E, Tanaka K (2007) Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 131: 1149-1163.
21. Kotoulas OB, Kalamidas SA, Kondomerkos DJ (2006) Glycogen autophagy in glucose homeostasis. Pathol Res Pract 202: 631-638.
22. Kraft C, Kijanska M, Kalle E, Lee SS, Semplicio G, Stoffel I, Brezovich A, Verma M, Hansmann I, Ammerer G, Hojmann K, Tooze S, Peter M (2012) Binding of the Atg1/ULK1 kinase to the ubiquitin-like protein Atg8 regulates autophagy. EMBO J 31: 3691-3703.
23. Kroemer G, Jäättelä M (2005) Lysosomes and autophagy in cell death control. Nat Rev Cancer 5: 886-897.
24. Li Y, Yang X, Su LJ, Flaig TW (2011) Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology 78(233): e7-13.
25. Mach L, Mort JS, Glossl J (1994) Maturation of human procathepsin B. Proenzyme activation and proteolytic processing of the precursor to the mature proteinase, in vitro, are primarily unimolecular processes. J Biol Chem 269: 13030-13035.
26. Marceau F, Bawolak MT, Lodge R, Bouthillier J, Gagné-Henley A, Gaudreault RC, Morissette G (2012) Cation trapping by cellular acidic compartments: beyond the concept of lysosomotropic drugs. Toxicol Appl Pharmacol 259: 1-12.
27. Mizushima M, Yoshimori T, Levine B (2010) Methods in mammalian autophagy research. Cell 140: 313-326.
28. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
29. Nadanaciva S, Lu S, Gebhard DF, Jessen BA, Pennie WD, Will Y (2011) A high content screening assay for identifying lysosomotropic compounds. Toxicol in vitro 25: 715-723.
30. Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, Morosi C, Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, Nicolai N, Braud De, Gianni AM, Salvioni R (2012) Pazopanib in advanced and platinum-resistant urothelial cancer: an openlabel, single group, phase 2 trial. Lancet Oncol 13: 810-816.
31. Noda T, Kim J, Huang WP, Baba M, Tokunaga C, Ohsumi Y, Klionsky DJ (2000) Apg9p/Cvt7 is an integral membrane protein required for transport vesicle formation in the Cvt and autophagy pathways. J Cell Biol 148: 465-480.
32. Notte A, Leclere L, Michiels C (2011) Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem Pharmacol 82: 427-434.
33. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597-3605.
34. Oh SH, Lim SC (2009) Endoplasmic reticulum stress-mediated autophagy/apoptosis induced by capsaicin (8-methyl-N-vanillyl-6-nonenamide) and dihydrocapsaicin is regulated by the extent of c-Jun NH2-terminal kinase/extracellular signal-regulated kinase activation in WI38 lung epithelial fibroblast cells. J Pharmacol Exp Ther 329: 112-122.
35. Puissant A, Colosetti P, Robert G, Cassuto JP, Raynaud S, Auberger P (2010) Cathepsin B release after imitanib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells. Leukemia 24: 115-124.
36. Pursiheimo JP, Rantanen K, Heikkinen PT, Johansen T, Jaakkola PM (2009) Hypoxia-Activated autophagy accelerates degradation of SQSTM1/p62. Oncogene 28: 334-344.
37. Raben N, Fukuda T, Gilbert AL, de Jong D, Thurberg BL, Mattaliano RJ, Meikle P, Hopwood JJ, Nagashima K, Nagaraju Ka, Plotz PH (2005) Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther 11: 48-56.
38. Rodriguez A, Durán A, Selloum M, Champy MF, Diez-Guerra FJ, Flores JM, Serrano M, Auwerx J, Diaz-Meco MT, Moscat J (2006) Mature-onset obesity and insulin-resistance in mice deficient in the signaling adapter p62. Cell Metab 3: 211-222.
39. Rosenbluth JM, Pietenpol JA (2009) mTOR regulates autophagy-Associated genes downstream of p73. Autophagy 5: 114-116.
40. Rosenfeld EL (1975) Alpha-glucosidases (gamma-Amylases) in human and animal organisms. Pathol Biol (Paris) 23: 71-84.
41. Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y (2012) A possible involvement of p62/sequestosome-1 in the process of biliary epithelial autophagy and senescence in primary biliary cirrhosis. Liver Int 32: 487-499.
42. Schmukler E, Shai B, Ehrlich M, Pinkas-Kramarski R (2012) Neuregulin promotes imcomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition. PLoS One 7: e36828.
43. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE (2003) SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63: 4009-4016.
44. Sivaprasad U, Basu A (2008) Inhibition of ERK attenuates autophagy and potentiates tumour necrosis factor-Alpha-induced cell death in MCF-7 cells. J Cell Mol Med 12: 1265-1271.
45. Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP (2009) Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 27: 391-399.
46. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061-1068.
47. Takeuchi A, Eto M, Shiota M, Tatsugami K, Yokomizo A, Kuroiwa K, Itsumi M, Naito S (2012) Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation. Int J Oncol 40: 1691-1696.
48. Tanida I (2011) Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal 14: 2201-2214.
49. Tchoupe JR, Moreau T, Gauthier F, Bieth JG (1991) Photometric or fluorometric assay of cathepsin B, L and H and papain using substrates with an aminotrifluoromethylcoumarin leaving group. Biochim Biophys Acta 1076: 149-151.
50. Turk B, Turk V (2009) Lysosome as "suicide bags" in cell death: myth or reality? J Biol Chem 284: 21783-21787.
51. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P, Thomson DB, Powel A, Friedlander M, Kotasek D, Harrup R, Gil T, Mazzeo F, Gennigens C, Krarup-Hansen A, Penel N, Rios M, Piperno-Neumann S, Duffaud F, Collard O, Egerer G, Wendtner CM, Bauer S, Gruenwald V, Steffen B, Folprecht G, Reichardt P, Siena S, Ferraresi V, Apice G, Comandone A, Roila F, Yokoyama R, Isu K, Sugiura H, Matsumine A, Ueda T, Ishii T, Ozaki T, Lee SH, Yun T, Lee KH, Rha SY, Ahn JH, Lee J, Martin Broto J, Casado Herraez A, Eriksson M, Engstroem K, Cavalli-Bjorkman N, Erlanson M, Wall N, Kerst J, Sleijfer S, Marples M, Woll P, Leahy MG, White JD, Hennig I, Conry R, Skubitz K, Fruehauf J, Singh D (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379: 1879-1886.
52. Willingham SB, Bergstralh DT, O'Connor W, Morrison AC, Taxman DJ, Duncan JA, Barnoy S, Venkatesan MM, Flavell RA, Deshmukh M, Hoffman HM, Ting JP (2007) Microbial pathogen-induced necrotic cell death mediated by the inflammasome components CIAS1/cryopyrin/NLRP3 and ASC. Cell Host Microbe 2: 147-159.
53. Wu CL, Ping SY, Yu CP, Yu DS (2012) Tyrosine kinase receptor inhibitortargeted combined chemotherapy for metastatic bladder cancer. Kaohsiung J Med Sci 28: 194-203.
54. Xie Z, Kliosky DJ (2007) Autophagosome formation: core machinery and adaptations. Nat Cell Biol 9: 1102-1109.
55. Yang Z, Kliosky DJ (2010) Eaten alive: a history of macroautophagy. Nat Cell Biol 12: 814-822.
56. Yoon CY, Lee JS, Kim BS, Jeong SJ, Hong SK, Byun SS, Lee SE (2011) Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. Korean J Urol 52: 55-63.
57. Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y (1991) Bafilomycin A1, a specific inhibitor of vacuolar-type H(\+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem 266: 17707-17712.
58. Young AR, Chan EY, Hu XW, Köchl R, Crawshaw SG, High S, Hailey DW, Lippincott-Schwartz J, Tooze SA (2006) Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosome. J Cell Sci 119: 3888-3900.
59. Zhao M, Antunes F, Eaton JW, Brunk UT (2003) Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur J Biochem 270: 3778-3786.
60. Zhu Z, Shen Z, Xu C (2012) Targeted therapy for advanced urothelial cancer of the bladder: where do we stand? Anticancer Agents Med Chem 12: 1081-1087.